Business
MIT Technology Review Insights and Globant Report: Three quarters of global pharma organizations are piloting or deploying agentic AI
Globant (NYSE: GLOB), a digitally native company that helps organizations thrive in a digital and AI-powered future, has partnered with MIT Technology Review Insights to launch a new report titled, "Transforming Commercial Pharma with Agentic AI." The report reveals that pharmaceutical companies are rapidly adopting AI agents across commercial and medical affairs, finding both strong momentum and clear priorities for the industry.
About this update from Globant S.a.
[{"type":"list","items":[{"val":[{"type":"text","content":"New global study of 250 pharma leaders shows rapid uptake of agentic AI; early adopters focus on market intelligence, patient support, compliance and data integration.","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"As the industry seeks to grasp over $100 billion a year in new growth opportunities, MIT Technology Review Insights claims: "agentic AI promises the next phase of transformation: from AI tool to AI coworker."","length":223,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":395,"olType":false},{"type":"text","content":"MADRID, Spain, Oct. 14, 2025 /PRNewswire/ -- Globant (NYSE: GLOB), a digitally native company that helps organizations thrive in a digital and AI-powered future, has partnered with MIT Technology Review Insights to launch a new report titled, "Transforming Commercial Pharma with Agentic AI." The report reveals that pharmaceutical companies are rapidly adopting AI agents across commercial and medical affairs, finding both strong momentum and clear priorities for the industry.","length":489,"tagName":"p"},{"type":"image","alt":"Transforming Commercial Pharma with Agentic AI","displaySize":"","headline":null,"caption":"Transforming Commercial Pharma with Agentic AI","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":263,"url":"https://media.zenfs.com/en/prnewswire.com/879ea2bcf199c98b0cd84afee0f81975"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WqwogsY8O8dCnQETiCMMdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/879ea2bcf199c98b0cd84afee0f81975","width":400,"height":263}},"href":"https://mma.prnewswire.com/media/2795871/1000x658___4_1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The report [available to download here] is based on a study conducted by MIT Technology Review Insights, the custom publishing division of MIT Technology Review, backed by the world's foremost technology institution, between May and July 2025. In total, 250 senior executives from the pharmaceuticals, biotech, and bioengineering industries took part, based in nine countries: Canada, US, France, Germany, Italy, Spain, UK, Brazil, and Switzerland.","length":452,"tagName":"p"},{"type":"text","content":"Key findings from the study",...